BÜCHLER, Tomáš, Jaroslav MICHÁLEK, Lucie KOVÁŘOVÁ, R. MUSILOVÁ and Roman HÁJEK. Dendritic cell-based immunotherapy for the treatment of hematological malignancies. Hematology. England: Maney Pub., 2003, vol. 8, No 2, p. 97-104. ISSN 1024-5332.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Dendritic cell-based immunotherapy for the treatment of hematological malignancies
Name in Czech Imunoterapie založená na dendritických buňkách při léčbě hematologických malignit
Authors BÜCHLER, Tomáš (703 Slovakia), Jaroslav MICHÁLEK (203 Czech Republic), Lucie KOVÁŘOVÁ (203 Czech Republic), R. MUSILOVÁ (203 Czech Republic) and Roman HÁJEK (203 Czech Republic, guarantor).
Edition Hematology, England, Maney Pub. 2003, 1024-5332.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Medicine
Keywords (in Czech) dendritické buňky; hematoonkologie; imunoterapie
Keywords in English dendritic cell; hematological malignancies; immunotherapy
Tags dendritic cell, hematological malignancies, Immunotherapy
Changed by Changed by: Mgr. Anna Potáčová, Ph.D., učo 44190. Changed: 23/6/2009 14:49.
Abstract
Dendritic cells (DCs) are professional antigen-presenting cells and are frequently used in current immunotherapy protocols. The administration of DCs loaded with tumor-associated proteins or peptides results in the induction of immune responses against different types of malignant cells. Methods for large-scale generation of DCs in a sufficient quality and quantity have permitted their use in clinical experiments. DC-based vaccines have already shown promise in follicular non-Hodgkin's lymphoma, and to some extent, in other hematological malignancies. Several strategies have been developed to boost their potency as a new and relatively non-toxic treatment modality. Our review focuses on clinical trials using DCs in the treatment of hematologic malignancies and on recent studies of the immunophenotype, development, and maturation of DCs may have an important impact on designing DC-based antitumor vaccines.
Abstract (in Czech)
Toto review je zaměřeno na klinické studie využivajících k léčbě hematoonkologických onemocnění dendritických buněk.
PrintDisplayed: 28/8/2024 03:08